These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9215602)

  • 21. In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay.
    Scheithauer W; Von Hoff DD; Clark GM; Shillis JL; Elslager EF
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):921-6. PubMed ID: 3770049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
    Pawlik CA; Israel M; Sweatman TW; Lothstein L
    Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimycotic effects of the novel antitumor agents fostriecin (CI-920), PD 113,270 and PD 113,271.
    Mamber SW; Okasinski WG; Pinter CD; Tunac JB
    J Antibiot (Tokyo); 1986 Oct; 39(10):1467-72. PubMed ID: 3781915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal toxicity of the anticancer drug fostriecin.
    de Jong RS; de Vries EG; Meijer S; de Jong PE; Mulder NH
    Cancer Chemother Pharmacol; 1998; 42(2):160-4. PubMed ID: 9654117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells.
    Gedik CM; Collins AR
    Nucleic Acids Res; 1990 Feb; 18(4):1007-13. PubMed ID: 2156221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells.
    Messner DJ; Romeo C; Boynton A; Rossie S
    J Cell Biochem; 2006 Sep; 99(1):241-55. PubMed ID: 16598789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of in vitro preconditioning responses of isolated pig and rabbit cardiomyocytes: effects of a protein phosphatase inhibitor, fostriecin.
    Armstrong SC; Kao R; Gao W; Shivell LC; Downey JM; Honkanen RE; Ganote CE
    J Mol Cell Cardiol; 1997 Nov; 29(11):3009-24. PubMed ID: 9405176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formal catalytic asymmetric total synthesis of fostriecin.
    Fujii K; Maki K; Kanai M; Shibasaki M
    Org Lett; 2003 Mar; 5(5):733-6. PubMed ID: 12605502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters.
    Hastie CJ; Cohen PT
    FEBS Lett; 1998 Jul; 431(3):357-61. PubMed ID: 9714542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
    J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase activity, expression of Bcl-2 and cell cycle regulation in doxorubicin resistant gastric carcinoma cell lines.
    Yoon KA; Ku JL; Yang JO; Park JG
    Int J Mol Med; 2003 Mar; 11(3):343-8. PubMed ID: 12579337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
    Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
    Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
    Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
    Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
    Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
    Valkov NI; Sullivan DM
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.